SCHEMBL25343903

SCHEMBL25343903

Fc1ccc(-n2ncc3c(Cl)nncc32)c(F)c1

nearest known ligand 0.49

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 8/20 0.49
▸ CYP17A1 P05093 4/20 0.40
▸ CYP1A2 P05177 2/20 0.40
▸ SCN9A Q15858 5/20 0.38
▸ NPC1 O15118 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25343352 0.83 MAPK14 (0.49) MAPK14CYP17A1CYP1A2SCN9ANPC1
SCHEMBL12670788 0.80 MAPK14 (0.45) MAPK14CYP17A1CYP1A2L3MBTL1
SCHEMBL25344046 0.78 CYP17A1 (0.46) MAPK14CYP17A1CYP1A2SCN9ANPC1
SCHEMBL30568414 0.72 CYP17A1 (0.53) MAPK14CYP17A1CYP1A2NPC1RAB9A
SCHEMBL839701 0.72 CYP17A1 (0.53) MAPK14CYP17A1CYP1A2NPC1RAB9A
SCHEMBL25343725 0.72 CYP17A1 (0.46) MAPK14CYP17A1CYP1A2NPC1RAB9A
SCHEMBL25342657 0.72 CYP17A1 (0.46) MAPK14CYP17A1CYP1A2SCN9ANPC1
SCHEMBL305521 0.70 SCN9A (0.48) MAPK14CYP17A1CYP1A2SCN9A
SCHEMBL25342945 0.70 SCN9A (0.45) CYP17A1CYP1A2SCN9A
SCHEMBL25344723 0.70 CYP17A1 (0.44) MAPK14CYP17A1CYP1A2SCN9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4472739-A1 IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2024-12-11 — — EP disclosed
WO-2023148129-A1 IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2023-08-10 — — WO disclosed
WO-2023148129-A1 IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2023-08-10 — — WO disclosed
Send feedback